192 related articles for article (PubMed ID: 17434832)
1. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
4. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
8. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
Freise KJ; Martín-Jiménez T
J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
[TBL] [Abstract][Full Text] [Related]
15. No evidence of gemcitabine accumulation during weekly administration.
de Lange SM; van der Born K; Kroep JR; Jensen HA; Pfeiffer P; Cleverly A; van Groeningen CJ; Peters GJ
Eur J Clin Pharmacol; 2005 Dec; 61(11):843-9. PubMed ID: 16283278
[TBL] [Abstract][Full Text] [Related]
16. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
18. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
